



Anthony D. Sabatelli, Ph.D.

PATENT COUNSEL

asabatelli@wiggin.com

New Haven: +1 203 498 4365

Anthony is Patent Counsel in Wiggin and Dana's Corporate Department, where he focuses his practice in the Intellectual Property and Life Sciences Practice Groups. He is a former business executive with both in-house corporate and law firm experience, with specific expertise in biotechnology. Anthony is a seasoned intellectual property attorney, and he is well-versed in patent and Hatch-Waxman and regulatory law. He began his career as a research scientist and project manager, and he is an inventor on numerous patents. He is also a member of wiggin(x).

Although Anthony focuses his patent practice on the life sciences, his patent experience covers a broad array of technologies, including pharmaceuticals, small molecules, macromolecules, RNA and DNA, proteins, biotechnology, drug delivery systems, inorganic chemistry and metals, medical devices, polymers, personal care products, formulations, process chemistry, X-ray crystallography, mechanical devices, green chemistry, software, nanotechnology, analytical methods, research tools, and blockchain technology. The insightful, practical, and business-oriented service he provides to his clients include, patent preparation and prosecution, foreign patent prosecution, patent searching and interpretation, patentability opinions, freedom-of-operation opinions, and landscape and competitive intelligence analyses. Additionally, Anthony has helped his clients build and manage their portfolios through patent life cycle management and time-line projection tools.

Anthony frequently writes and speaks on a range of topics, including developments in patent subject matter eligibility (35 USC § 101), the microbiome, nanotechnology, oncology, green chemistry, energy issues, the intersection of patent and regulatory law, and scientific analytical tools for supporting patent litigation. He has testified at public hearings at the US Patent and Trademark Office on patent subject matter eligibility and is a regular guest contributor to Patent Docs, www.patentdocs.com, a Patent Law Weblog that publishes on a broad range of patent topics.

He is an avid supporter of the bioscience industry. Anthony is an active member of BioCT, the advocacy organization for the industry where he has served as a former director and also former chair of its government advocacy committee, where he has testified at the state level on issues relevant to the industry and public health.

Before joining Wiggin and Dana, Anthony was Partner and Chair of the Biotech and Life Sciences Practice at a boutique law firm. Previously, Anthony was Vice President and General Counsel and Chief Patent Counsel at Melinta Therapeutics, Inc. Prior to this, he was Assistant Counsel at Merck & Co., Inc. and Patent Counsel at Procter & Gamble.

Anthony received his J.D., *cum laude*, from the Salmon P. Chase College of Law. He received his Ph.D., with Honors, in Organic Chemistry from Yale University, and his B.S., *summa cum laude*, in Chemistry from Fairfield University.

Education

- Salmon P. Chase College of Law (J.D., 1994)
 - cum laude
- Yale University (Ph.D., 1984)
 - With Honors
- Fairfield University (B.S., 1979)
 - summa cum laude

Bar Admissions

- U.S. Patent and Trademark Office
- Ohio

Memberships and Affiliations

- BioCT
 - Former Board of Directors
 - Government Affairs Committee (January 2015 to present)
 - Member (2011-present)
- Yale Alumni Association
 - Board of Governors (July 2016 to present)
 - Past Chair, Executive Board Graduate School Alumni Association
- Yale Alumni Fund
 - Board Member (July 2018 to present)
- Nicholas & Viola Spinelli Educational Foundation
 - Vice President and Director (October 2016 to present)

Publications

May 8, 2026

A Lesson from the Federal Circuit: “About” or “Approximately” in Patent Claims May Render Them Indefinite and Invalid

March 25, 2026

Design Patents Enter the Virtual World: USPTO Expands Protection to Projections, Holograms, and

Virtual/Augmented Reality Interfaces

February 11, 2026

Expediting U.S. Patent Prosecution to Guide Foreign Filing Strategies

January 5, 2026

To Expedite or Not To Expedite—That is the Question. Patent Strategies in the Face of USPTO Examination Backlogs

December 12, 2025

Supreme Court Declines Tackling Important Machine Learning Patent Case

August 19, 2025

Weighing in on Alice, the Federal Circuit Rejects Mechanical Automation as an Abstract Idea

July 29, 2025

Federal Circuit Broadens Reach of Patent Prosecution History Estoppel

June 30, 2025

Bartz v. Anthropic: First Court Decision on Fair Use Defense in LLM Training

May 13, 2025

Driving the Machine Learning Engine is not Enough

July 1, 2024

The New Obviousness Standard for U.S. Design Patents

August 17, 2022

Artificial Intelligence (AI) and Inventorship – Will the next blockbuster drug be denied patent protection?

April 6, 2021

Were Current Patent Judges Unconstitutionally Appointed?

February 26, 2020

Recent Developments in Intellectual Property Law

February 18, 2020

BioInsights Newsletter, Winter 2020

November 21, 2019

Our Take on the USPTO's Recent October 2019 Patent Eligibility Guidance

March 18, 2019

Antibody-Drug Conjugates: Further Patents on Linkers

Patent Docs

March 4, 2019

Recent Developments in Intellectual Property Law Newsletter